117 related articles for article (PubMed ID: 1285257)
21. [Prediction of recurrence of gastrointestinal cancer from standpoint of biological malignancies--tumor marker doubling time and its a half life period line].
Mai M; Takahashi Y
Hum Cell; 1993 Jun; 6(2):82-7. PubMed ID: 7692953
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
23. [Plasma levels of alpha-fetoprotein and carcinoembryonic antigen in patients with malignant gastrointestinal tumors].
Monteiro JC; Moreira MM; Pereira FE; de Oliveira LR; da Cunha EA; Leite JF; Castro e Sousa F
Acta Med Port; 1989; 2(6):245-52. PubMed ID: 2483025
[TBL] [Abstract][Full Text] [Related]
24. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of four serological tumor markers for the detection of breast cancer.
Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
[TBL] [Abstract][Full Text] [Related]
27. [Lack of prognostic significance of carcinoembryonic antigen (CEA) preoperative serum levels in patients with advanced larynx cancer].
Polberg K; Stepulak A; Stryjecka-Zimmer M; Kupisz K; Zawiślak J
Przegl Lek; 2006; 63(2):68-71. PubMed ID: 16969905
[TBL] [Abstract][Full Text] [Related]
28. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
29. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
30. A new radioimmunoassay detecting early stages of colon cancer: a comparison with CEA, AFP, and Ca 19-9.
Chester SJ; Maimonis P; Vanzuiden P; Finklestein M; Bookout J; Vezeridis MP
Dis Markers; 1991; 9(5):265-71. PubMed ID: 1724634
[TBL] [Abstract][Full Text] [Related]
31. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
Gebauer G; Müller-Ruchholtz W
Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706
[TBL] [Abstract][Full Text] [Related]
32. [The value of tumor markers in colorectal cancer].
Peters KM; Grundmann R
Leber Magen Darm; 1989 Jan; 19(1):18-25. PubMed ID: 2927234
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical study on hepatic tumors--KM01 stains compared with AFP, CEA, CA19-9 and RAS P21.
Hanabata M; Ohyanagi H; Saitoh Y; Itoh H
Kobe J Med Sci; 1991 Apr; 37(2):81-96. PubMed ID: 1717740
[TBL] [Abstract][Full Text] [Related]
35. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
36. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
37. Significance of CEA, AFP, SP1 and HCG as tumor markers in ovarian carcinoma.
Pulay T; Csömör S; Mészáros K; Szarka G; Csabay L; Szinnyai A
Neoplasma; 1987; 34(5):595-600. PubMed ID: 2447510
[TBL] [Abstract][Full Text] [Related]
38. Carcinoembryonic antigen (CEA)--a useful marker for the detection of recurrent disease in endometrial carcinoma patients.
Bruns F; Micke O; Halek G; Schäfer U; Willich N
Anticancer Res; 2003; 23(2A):1103-6. PubMed ID: 12820355
[TBL] [Abstract][Full Text] [Related]
39. Serum tetranectin and CA125 in endometrial adenocarcinoma.
Lundstrøm MS; Høgdall CK; Nielsen AL; Nyholm HC
Anticancer Res; 2000; 20(5C):3903-6. PubMed ID: 11268474
[TBL] [Abstract][Full Text] [Related]
40. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
